Reverse transcriptase-IN-1
CAS No. 2380001-43-2
Reverse transcriptase-IN-1( —— )
Catalog No. M26414 CAS No. 2380001-43-2
Reverse transcriptase-IN-1 is a diarylbenzopyrimidine (DABP) analogue and a potent inhibitor of HIV-1 nonnucleoside reverse transcriptase with an IC50of 13.7 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 200 | Get Quote |
|
10MG | 290 | Get Quote |
|
25MG | 492 | Get Quote |
|
50MG | 709 | Get Quote |
|
100MG | 972 | Get Quote |
|
500MG | 1962 | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameReverse transcriptase-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionReverse transcriptase-IN-1 is a diarylbenzopyrimidine (DABP) analogue and a potent inhibitor of HIV-1 nonnucleoside reverse transcriptase with an IC50of 13.7 nM.
-
DescriptionReverse transcriptase-IN-1 is a diarylbenzopyrimidine (DABP) analogue and a potent inhibitor of HIV-1 nonnucleoside reverse transcriptase with an IC50of 13.7 nM. (In Vitro):Reverse transcriptase-IN-1 has antiviral activity with EC50 values of 3.4 nM, 4.3 nM and 3.6 nM for HIV-1 IIIB, E138K and K103N mutants, respectively.(In Vivo):The PK study and safety assessment of Reverse transcriptase-IN-1 shows that it is absorbed with mean residence times (MRTs) of 11.8 hours (5 mg/kg, p.o.) and 11.4 hours (1 mg/kg, i.v.) at these two doses. The Cmax of Reverse transcriptase-IN-1 is 39.9 ng/mL at a dose of 5 mg/kg. The oral bioavailability of Reverse transcriptase-IN-1 is significantly improved to 16.5% at a dose of 5 mg/kg in rats. The intrinsic rat microsome clearance of Reverse transcriptase-IN-1 is 33.2 μL/min/mg proteins.
-
In Vitro——
-
In VivoThe oral bioavailability of Reverse transcriptase-IN-1 (Compound 12z) is significantly improved to 16.5% at a dose of 5 mg/kg in rats. The intrinsic rat microsome clearance of Reverse transcriptase-IN-1 is 33.2 μL/min/mg proteins. The PK study and safety assessment of Reverse transcriptase-IN-1 shows that it is absorbed with mean residence times (MRTs) of 11.8 hours (5 mg/kg, p.o.) and 11.4 hours (1 mg/kg, i.v.) at these two doses. The Cmax of Reverse transcriptase-IN-1 is 39.9 ng/mL at a dose of 5 mg/kg. A single-dose toxicity test of Reverse transcriptase-IN-1 in rats shows no mortality, and there is no abnormal body weight decrease in the animals in the week following an intragastrical dose at 293 mg/kg body weigh. The above results indicate that Reverse transcriptase-IN-1 could be an orally bioavailable candidate for human HIV-1 infection research.
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHIV
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2380001-43-2
-
Formula Weight447.458
-
Molecular FormulaC25H17N7O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (27.94 mM)
-
SMILESCc1cc(\C=C\C#N)cc(c1Nc1nc(Nc2ccc(cc2)C#N)nc2ccccc12)[N+]([O-])=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Atta-ur-Rahman, et, al. Antifungal aryltetralin lignans from leaves of Podophyllum hexandrum. Phytochemistry. 1995 Sep; 40(2): 427-431.
molnova catalog
related products
-
KNI-1657
KNI-1657 (KNI1657) is a highly potent HIV-1 protease inhibitor (97% inhibition at 1 nM) with high sensitivity against lopinavir/ritonavir- or darunavir-resistant strains.
-
Atazanavir sulfate
A highly potent HIV-1 protease inhibitor that exhibits potent anti-HIV activity EC50 of 2.6-5.3 nM and EC90 of 9-15 nM in cell culture.
-
Benzalphthalide
Benzalphthalide is a chemical compound with anti-HIV activity.